TB Alliance

Dr. Mel Spigelman Named in Fast Company’s Annual List of the Most Creative People in Business

August 4, 2020

NEW YORK (August 4, 2020)—Fast Company today announced its 11th annual list of the Most Creative People in Business, honoring

August 3, 2020

Pretomanid, developed by the non-profit TB Alliance, has received EU marketing authorisation in combination regimen with bedaquiline and linezolid in

July 29, 2020

As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those

July 22, 2020

Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved

July 9, 2020

NEW YORK (July 9, 2020)—TB Alliance supports recent commentaries including those in The Lancet and from the Global Health Council

June 25, 2020

As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those

June 18, 2020

NEW YORK (June 18, 2020)—Children represent an estimated 11 percent of all tuberculosis (TB) cases, and about 1.1 million children

June 5, 2020

TB Alliance President and CEO Mel Spigelman, M.D. shared the following message to all TB Alliance employees and consultants in

June 2, 2020

Guilford, Conn., June 2, 2020, InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning

May 28, 2020

The NPAP is designed for patients in countries where regulatory approval or other access mechanisms for pretomanid are not yet